Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES: Methylene blue, once discarded due to its unsettling yet mild side effects, has now found a renewed place in the pharmacopoeia of modern medicine. The continued spread of drug-resistant Plasmodium vivax and Plasmodium falciparum has also led to a recent re-examination of methylene blue's potent antimalarial properties. Here we examine the ex vivo susceptibility profile of Plasmodium spp. isolates to methylene blue; the isolates were from a region on the Thai-Myanmar border where there are increasing rates of failure when treating vivax malaria with chloroquine. METHODS: To do this we used a newly developed ex vivo susceptibility assay utilizing flow cytometry and a portable flow cytometer with a near-UV laser. RESULTS: P. vivax (median methylene blue IC50 3.1 nM, IQR 1.7-4.3 nM) and P. falciparum (median methylene blue IC50 1.8 nM, IQR 1.6-2.3 nM) are susceptible to methylene blue treatment at physiologically relevant levels. Unfortunately, the addition of chloroquine to combination treatments with methylene blue significantly reduces the ex vivo effectiveness of this molecule. CONCLUSIONS: Our data support further efforts to employ methylene blue as a safe, low-cost antimalarial to treat drug-resistant malaria.

Original publication

DOI

10.1093/jac/dku326

Type

Journal article

Journal

J Antimicrob Chemother

Publication Date

01/2015

Volume

70

Pages

124 - 129

Keywords

Plasmodium falciparum, Plasmodium vivax, drug sensitivity assays, drug susceptibility assays, Antimalarials, Cell Survival, Chloroquine, Drug Resistance, Flow Cytometry, Humans, Inhibitory Concentration 50, Laser Scanning Cytometry, Malaria, Vivax, Methylene Blue, Myanmar, Parasitic Sensitivity Tests, Plasmodium vivax, Thailand